Journal of Gastrointestinal Surgery

, Volume 11, Issue 7, pp 929–944 | Cite as

Detection and Management of Extrahepatic Colorectal Cancer in Patients with Resectable Liver Metastases

  • Yolanda Y. L. Yang
  • James W. Fleshman
  • Steven M. Strasberg


The presence of extrahepatic disease has a great effect on the management of patients with metastatic colorectal cancer in the liver. FDG-PET scanning is currently the most sensitive way of detecting extrahepatic metastases in such patients. This is supported by 10 studies, which show that FDG-PET scan will discover extrahepatic disease in about one in six patients who have completed standard imaging. Staging laparoscopy is another means of detecting extrahepatic disease. Its role remains undefined especially in patients who have had FDG-PET scans. It should probably be restricted to patients with high clinical risk scores. In terms of treatment, patients with recurrence at the primary colorectal site as well as resectable liver metastases appear to benefit from resection of both sites provided that R0 resections can be obtained. Resection of involved hepatic pedicle lymph nodes in patients with resectable liver metastases is associated with poor outcome. The situation regarding patients with peritoneal and liver metastases bears a strong resemblance to that of primary site recurrence and liver metastases. Very acceptable survival can be expected if the peritoneal disease can be eradicated. Information regarding treatment of lung and liver metastases is the most complete of any of these areas. Good results may be expected if all the disease can be cleared. Caution is required in interpreting claims of good survival when study numbers are small and confidence intervals of data are not provided.


Extrahepatic colorectal cancer Colorectal cancer Liver metastasis Liver resection FDG-PET scan Colorectal lung metastases Colorectal peritoneal metastases Colorectal portal lymph node metastases 


  1. 1.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002;224:748–756.Google Scholar
  2. 2.
    Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 1177;41:1177–1189.Google Scholar
  3. 3.
    Bipat S, van Leeuwen MS, Comans EFI, Pijl MEJ, Bossuyt PMM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology 2005;237:123–131.PubMedCrossRefGoogle Scholar
  4. 4.
    Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282–287.PubMedCrossRefGoogle Scholar
  5. 5.
    Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703–707.PubMedGoogle Scholar
  6. 6.
    Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan, D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study [see comment]. Ann Surg 2001;233:293–299.PubMedCrossRefGoogle Scholar
  7. 7.
    Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastroint Surg 2004;8:150–157.CrossRefGoogle Scholar
  8. 8.
    Rosa F, Meimarakis G, Stahl A, Bumm R, Hahn K, Tatsch K, et al. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuclear Medizin 2004;43:135–140.Google Scholar
  9. 9.
    Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002;20:388–395.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000;21:793–798.PubMedCrossRefGoogle Scholar
  11. 11.
    Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Europ J Surg Oncol 2004;30(3):286–291.CrossRefGoogle Scholar
  13. 13.
    Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, & Pruvot, FR. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Brit J Surg 2005;92:362–369.PubMedCrossRefGoogle Scholar
  14. 14.
    Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027–1034.PubMedCrossRefGoogle Scholar
  15. 15.
    Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin North America 2003;12:165–192.Google Scholar
  16. 16.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318; discussion 318–321.PubMedCrossRefGoogle Scholar
  17. 17.
    Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al. Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll of Surg 1999;189:291–299.CrossRefGoogle Scholar
  18. 18.
    Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. European J Nuc Med Mol Imag 2002;29:915–921.CrossRefGoogle Scholar
  19. 19.
    Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001;8:779–786.PubMedCrossRefGoogle Scholar
  20. 20.
    Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130:636–643; discussion 643–644.PubMedCrossRefGoogle Scholar
  21. 21.
    Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). European Journal of Cancer 2001;37:862–869.PubMedCrossRefGoogle Scholar
  22. 22.
    Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.PubMedCrossRefGoogle Scholar
  23. 23.
    Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Col & Rect 2005;48:1900–1912.CrossRefGoogle Scholar
  24. 24.
    Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Canc Res 2005;11:2785–2808.CrossRefGoogle Scholar
  25. 25.
    Rahusen FD, Cuesta MA, Borgstein PJ, Bleichrodt RP, Barkhof F, Doesburg T, et al. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography [see comment]. Ann Surg 1999;230:31–37.PubMedCrossRefGoogle Scholar
  26. 26.
    Jarnagin WR, Conlon K, Bodniewicz J, Dougherty E, DeMatteo RP, Blumgart LH, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001;91(6):1121–1128.PubMedCrossRefGoogle Scholar
  27. 27.
    de Castro SM, Tilleman EH, Busch OR, van Delden OM, Lameris JS, van Gulik TM, et al. Diagnostic laparoscopy for primary and secondary liver malignancies: Impact of improved imaging and changed criteria for resection. Ann Surg Oncol 2004;11:522–529.PubMedCrossRefGoogle Scholar
  28. 28.
    Grobmyer SR, Fong Y, D’Angelica M, Dematteo RP, Blumgart LH, Jarnagin WR. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg 2004;139:1326–1330.PubMedCrossRefGoogle Scholar
  29. 29.
    Koea J, Rodgers M, Thompson P, Woodfield J, Holden A, McCall J. Laparoscopy in the management of colorectal cancer metastatic to the liver. ANZ J Surg 2004;74:1056–1059.PubMedCrossRefGoogle Scholar
  30. 30.
    Thaler K, Kanneganti S, Khajanchee Y, Wilson C, Swanstrom L, Hansen PD. The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch Surg 2005;140:727–734.PubMedCrossRefGoogle Scholar
  31. 31.
    Luque-de Leon E, Tsiotos GG, Balsiger B, Barnwell J, Burgart LJ, Sarr MG. Staging laparoscopy for pancreatic cancer should be used to select the best means of palliation and not only to maximize the resectability rate. J Gastrointest Surg 1999;3:111–117.PubMedCrossRefGoogle Scholar
  32. 32.
    Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. Am J Roentgenol 2002;178:353–358.Google Scholar
  33. 33.
    Bollschweiler E. Benefits and limitations of Kaplan–Meier calculations of survival chance in cancer surgery. Langenbeck’s Arch Surg 2003;388:239–244.CrossRefGoogle Scholar
  34. 34.
    Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O’Connell MJ, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 2003;237:502–508.PubMedCrossRefGoogle Scholar
  35. 35.
    Vermaas M, Ferenschild FT, Nuyttens JJ, Marinelli AW, Wiggers T, van der Sijp JR, et al. Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Col & Rect 2005;48:918–928.CrossRefGoogle Scholar
  36. 36.
    Bakx R, van Tinteren H, van Lanschot JJ, Zoetmulder FA. Surgical treatment of locally recurrent rectal cancer. Europ J Surg Oncol 2004;30:857–863.Google Scholar
  37. 37.
    Shoup M, Guillem JG, Alektiar KM, Liau K, Paty PB, Cohen AM, et al. Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy. Dis Col & Rect 2002;45:585–592.CrossRefGoogle Scholar
  38. 38.
    Yamada K, Ishizawa T, Niwa K, Chuman Y, Akiba S, Aikou T. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Brit J Surg 2001;8:988–993.CrossRefGoogle Scholar
  39. 39.
    Hartley JE, Lopez RA, Paty PB, Wong WD, Cohen AM, Guillem JG. Resection of locally recurrent colorectal cancer in the presence of distant metastases: Can it be justified? Ann Surg Oncol 2003;10:227–233.PubMedCrossRefGoogle Scholar
  40. 40.
    Bowne WB, Lee B, Wong WD, Ben-Porat L, Shia J, Cohen AM, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: An analysis of 100 cases. Dis Col & Rect 2005;48:897–909.CrossRefGoogle Scholar
  41. 41.
    August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer. Cancer 1985;55:1490–1494.PubMedCrossRefGoogle Scholar
  42. 42.
    Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: A prospective study. [see comment]. Ann Surg Oncol 2002;9:430–438.PubMedCrossRefGoogle Scholar
  43. 43.
    Kokudo N, Sato T, Seki M, Ohta H, Azekura K, Ueno M, et al. Hepatic lymph node involvement in resected cases of liver metastases from colorectal cancer. Dis Col & Rect 1999;42(10):1285–1290; discussion 1290–1291.CrossRefGoogle Scholar
  44. 44.
    Elias D, Saric J, Jaeck D, Arnaud JP, Gayet B, Rivoire M, et al. Prospective study of microscopic lymph node involvement of the hepatic pedicle during curative hepatectomy for colorectal metastases. Brit J Surg 1996;83:942–945.PubMedCrossRefGoogle Scholar
  45. 45.
    Couinaud C. Lymphatic drainage of the liver. In Couinaud C, ed. Controlled hepatectomies and exposure of the intrahepatic bile ducts. Anatomical and technical study. Paris, France: C. Couinaud, 1981.Google Scholar
  46. 46.
    Tsuji T, Hiraoka T, Kanemitsu K, Takamori H, Tanabe D, Tashiro S. Lymphatic spreading pattern of intrahepatic cholangiocarcinoma. Surgery 2001;129(4):401–407.PubMedGoogle Scholar
  47. 47.
    Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin North America 2003;12:221–229.CrossRefGoogle Scholar
  48. 48.
    Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004;198:884–891.PubMedCrossRefGoogle Scholar
  49. 49.
    Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert, JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Brit J Surg 1997;84:1081–1084.PubMedCrossRefGoogle Scholar
  50. 50.
    Nakamura S, Suzuki S, Konno H. Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J HPB Surg 1999;6:16–22.Google Scholar
  51. 51.
    Rodgers MS, McCall, JL. Surgery for colorectal liver metastases with hepatic lymph node involvement: A systematic review [see comment] [erratum appears in Br J Surg 2001 Mar;88(3):472]. Brit J Surg 2000;87:1142–1155.PubMedCrossRefGoogle Scholar
  52. 52.
    Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North America 1989;69:339–359.Google Scholar
  53. 53.
    Nordlinger B, Jaeck D, Guiguet M, Vaillant J, Balladur PJCS. Resection chiurgicale des metastates hepatique. Enquete de l’Association Francaise de Chirurgie. In: Monographies de l’Association Francaise de Chirurgie. Traitement Des Metastases Hepatiques Des Cancer Colorectaux. Paris: Springer, 1992 pp 129–146.Google Scholar
  54. 54.
    Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Sem Oncol 2005;32(6 Suppl 9):S68–S73.CrossRefGoogle Scholar
  55. 55.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [see comment]. J Clin Oncol 2003;21:3737–3743.PubMedCrossRefGoogle Scholar
  56. 56.
    Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284–3292.PubMedCrossRefGoogle Scholar
  58. 58.
    Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Brit J Surg 1990;77:1241–1246.PubMedCrossRefGoogle Scholar
  59. 59.
    McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992;127:1403–1406.PubMedGoogle Scholar
  60. 60.
    Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North America 2002;82:1075–1090.CrossRefGoogle Scholar
  61. 61.
    Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979.PubMedCrossRefGoogle Scholar
  62. 62.
    Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006;202:468–475.PubMedCrossRefGoogle Scholar
  63. 63.
    Regnard J-F, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214–218.PubMedCrossRefGoogle Scholar
  64. 64.
    Ike H, Shimada H, Togo S, Yamaguchi S, Ichikawa Y, Tanaka K. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. British Journal of Surgery 2002;89(9):1164–1168.PubMedCrossRefGoogle Scholar
  65. 65.
    Murata S, Moriya Y, Akasu T, Fujita S, Sugihara, K. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;83:1086–1093.PubMedCrossRefGoogle Scholar
  66. 66.
    Kobayashi K, Kawamura M, Ishihara T. Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. Journal of Thoracic & Cardiovascular Surgery 1999;118(6);1090–1096.CrossRefGoogle Scholar
  67. 67.
    Robinson BJ, Rice TW, Strong SA, Rybicki LA, Blackstone, EH. Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? Journal of Thoracic and Cardiovascular Surgery 1999;117:66–75.PubMedCrossRefGoogle Scholar
  68. 68.
    Nagakura S, Shirai Y, Yamato Y, Yokoyama N, Suda T, Hatakeyama K. Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001;193:153–160.PubMedCrossRefGoogle Scholar
  69. 69.
    Mineo TC, Ambrogi V, Tonini G, Bollero P, Roselli M, Mineo D, et al. Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003;197:386–391.PubMedCrossRefGoogle Scholar
  70. 70.
    Reddy RHV, Kumar B, Shah R, Mirsadraee S, Papagiannopoulos K, Lodge P, et al. Staged pulmonary and hepatic metastasectomy in colorectal cancer-is it worth it? Europ J Cardio-Thorac Surg 2004;25:151–154.CrossRefGoogle Scholar
  71. 71.
    Patel NA, Keenan RJ, Medich DS, Woo Y, Celebrezze J, Santucci T, et al. The presence of colorectal hepatic metastases does not preclude pulmonary metastasectomy. Am Surg 2003;69:1047–1053.PubMedGoogle Scholar
  72. 72.
    Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Kato A, et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;82:274–278.PubMedCrossRefGoogle Scholar
  73. 73.
    Lehnert T, Knaebel HP, Dück M, Bülzebruck H, Herfarth C. Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Brit J Surg 1999;86:241–243.PubMedCrossRefGoogle Scholar
  74. 74.
    Labow DM, Buell JF, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases—is resection indicated? The Cancer Journal 2002;8:342–347.PubMedGoogle Scholar
  75. 75.
    Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900–909.PubMedCrossRefGoogle Scholar
  76. 76.
    Strasberg SM. Letter to editor. Ann Surg Onc. in press, Published online at doi:  10.1245/s10434-006-9088-7
  77. 77.
    Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274–280.PubMedCrossRefGoogle Scholar
  78. 78.
    Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Brit J Surg 2003;90:567–574.PubMedCrossRefGoogle Scholar
  79. 79.
    Garcia-Aguilar J, Cromwell JW, Marra C, Lee, S-H, Madoff RD, Rothenberger, DA. Treatment of locally recurrent rectal cancer. Dis Colon & Rectum 2001;44:1743–1748.CrossRefGoogle Scholar
  80. 80.
    Lopez-Kostner F, Fazio VW, Vignali A, Rybicki LA, Lavery IC. Locally recurrent rectal cancer predictors and success of salvage surgery. Dis Colon & Rectum 2001;44:173–178.CrossRefGoogle Scholar
  81. 81.
    Wiig JN, Larsen SG, Dueland S, Giercksky KE. Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol 2005;92:70–75.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Yolanda Y. L. Yang
    • 1
  • James W. Fleshman
    • 2
  • Steven M. Strasberg
    • 3
  1. 1.The Permanente Medical GroupKaiser, South San FranciscoSan FranciscoUSA
  2. 2.Section of Colorectal SurgeryWashington University in St. Louis and Siteman Cancer CenterSt. LouisUSA
  3. 3.Section of Hepatobiliary-Pancreatic SurgeryWashington University in Saint Louis and Siteman Cancer CenterSt. LouisUSA

Personalised recommendations